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Abstract: Objective: It remains unclear whether very early onset 
psychosis (VEOP; ≤ 12 years of age) and early onset psychosis (EOP; onset 
13-17 years of age) are homogeneous in their clinical presentation. We 
investigated the predictive value of age of psychosis onset for severity, 
functioning and demographic variation by: 1) comparing groups based on 
traditional cut-offs for age of psychosis onset, and 2) using receiver 
operating characteristic (ROC)-curve calculations, without a priori age 
of onset cut-offs.  
 
Method: Participants were 88 (45 female, 43 male) children and 
adolescents with a recent onset of psychosis (age range=6.7-17.5 years; 
M=13.74, SD=2.37).  
 
Results: The VEOP group had significantly shorter duration of untreated 
illness and untreated psychosis, and lower functioning than the EOP 
group. The VEOP and EOP groups did not differ significantly on gender 
proportion, urbanicity, psychotic diagnosis, family history of psychotic 
disorder, psychotic, depressive and anxiety symptoms or IQ. When applying 
ROC-curves to the lowest three quartiles of positive psychotic symptoms 
scores, the optimal age-cut-off was 14.0 years (sensitivity=0.62; 
specificity=0.75). For the highest quartile of functioning scores, the 
optimal differentiating cut-off for age of psychosis onset was 14.7 years 
(sensitivity=0.71; specificity=0.70).  
  
Conclusions: Larger samples of patients, assessed at presentation and 
followed-up, are necessary to clearly examine clinical presentation and 
outcome as a function of social and neural development to better 
understand if the differentiation between VEOP and EOP is justified . 
This will aid the development of predictive diagnostic tools, more 
accurate prognosis prediction, and age-tailored therapeutic 
interventions.  
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Introduction section: “Schizophrenia is a heterogeneous clinical syndrome of unknown 
aetiology, comprising a number of psychopathological domains and patients vary 
considerably in which pathologies are manifest (Insel, 2010). In accordance with this 
definition, symptoms of schizophrenia are heterogeneous, even within the same age group 
(Carpenter & Buchanan, 1989). Besides the heterogeneity of the clinical presentation, some 
differences related to the age of onset (i.e. premorbid abnormalities, longer duration of 
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Abstract 
 
Objective: It remains unclear whether very early onset psychosis (VEOP; ≤ 12 years of age) and 
early onset psychosis (EOP; onset 13-17 years of age) are homogeneous in their clinical 
presentation. We investigated the predictive value of age of psychosis onset for severity, 
functioning and demographic variation by: 1) comparing groups based on traditional cut-offs for 
age of psychosis onset, and 2) using receiver operating characteristic (ROC)-curve calculations, 
without a priori age of onset cut-offs.  
 
Method: Participants were 88 (45 female, 43 male) children and adolescents with a recent onset of 
psychosis (age range=6
.
7-17.5 years; M=13
.
74, SD=2
.
37).  
 
Results: The VEOP group had significantly shorter duration of untreated illness and untreated 
psychosis, and lower functioning than the EOP group. The VEOP and EOP groups did not differ 
significantly on gender proportion, urbanicity, psychotic diagnosis, family history of psychotic 
disorder, psychotic, depressive and anxiety symptoms or IQ. When applying ROC-curves to the 
lowest three quartiles of positive psychotic symptoms scores, the optimal age-cut-off was 14.0 years 
(sensitivity=0.62; specificity=0.75). For the highest quartile of functioning scores, the optimal 
differentiating cut-off for age of psychosis onset was 14
.
7 years (sensitivity=0.71; specificity=0.70).  
  
Conclusions: Larger samples of patients, assessed at presentation and followed-up, are necessary to 
clearly examine clinical presentation and outcome as a function of social and neural development to 
better understand if the differentiation between VEOP and EOP is justified . This will aid the 
development of predictive diagnostic tools, more accurate prognosis prediction, and age-tailored 
therapeutic interventions.  
 
Key-words: very early and early onset psychosis, first-episode psychosis, schizophrenia, childhood 
onset, ROC-curves 
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1 Introduction  
Schizophrenia is a heterogeneous clinical syndrome of unknown aetiology, comprising a number of 
psychopathological domains and patients vary considerably in which pathologies are manifest 
(Insel, 2010). In accordance with this definition, symptoms of schizophrenia are heterogeneous, 
even within the same age group (Carpenter & Buchanan, 1989). Besides the heterogeneity of the 
clinical presentation, some differences related to the age of onset (i.e. premorbid abnormalities, 
longer duration of untreated psychosis [DUP], poorer outcome) have been highlighted (Armando et 
al, 2015). Consequently, the need of age-specific research in the area of psychosocial treatments for 
children and adolescents with schizophrenia has been argued (Tiffin et al, 2013). 
In accordance with this evidence, a distinction has traditionally been made between adult-
onset psychosis (AOP; ≥ 18 years of age) and early onset psychosis (EOP; onset <18 years of age), 
which occurs in approximately one-third of all patients diagnosed with a psychotic disorder 
(Madaan et al., 2008). While this cut-off is arbitrary, there is evidence that psychotic illness which 
begins before the age of 18 tends to be more severe than AOP (Rabinowitz et al., 2006; Reichert et 
al., 2008; Kumra & Schultz, 2008; Diaz-Caneja et al., 2015). Compared to AOP, EOP is more 
strongly associated with premorbid social impairments, DUP (Hollis, 2003; Schimmelmann et al., 
2007), a more severe clinical course (Werry et al., 1991; Eggers et al., 1997), more severe 
premorbid neurodevelopmental abnormalities (Vourdas et al., 2003), greater genetic loading 
(Kumra & Schultz, 2008), and more severe negative symptoms (Pencer et al., 2005; Kao et al., 
2010).  
While the differences between AOP and EOP are well supported, there is still debate 
regarding whether EOP should be considered as a homogeneous entity. Most commonly, the cut-off 
of psychosis onset at or before 12 years of age is used; that is, EOP with onset between 13 and 17 
years of age (sometimes referred to as adolescent onset psychosis) and very early onset psychoses 
(VEOP), with onset of illness at age 12 years or younger (often referred to as childhood onset 
schizophrenia). While many studies have investigated the clinical and neurocognitive features of 
VEOP specifically (see Kyriakopoulos et al., 2007 for a review), very few have directly compared 
the clinical characteristics of EOP and VEOP. Those that have demonstrate the long-term outcome 
of individuals with VEOP appears to be worse than EOP. These individuals do more poorly at 
school and are less likely to have been employed than individuals with EOP (Biswas et al., 2006). 
They have a longer first hospital admission and subsequently have a greater number of days in 
hospital each year (Rabinowitz et al., 2006). There is also meta-analytic evidence that anti-
psychotic medication initiated at a younger age is associated with an increased risk of side effects, 
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particularly weight gain, higher discontinuation rates and leaving school early (Stafford et al., 
2015). Evidence of neurocognitive variations according to age of psychosis onset is variable. 
Biswas and colleagues (Biswas et al., 2006) showed poorer cognitive function, namely IQ, memory 
and perceptuomotor skills, in individuals with VEOP compared to EOP. Conversely, Rhinewine et 
al. (2005) found no significant differences in the neurocognitive performance of VEOP and EOP 
groups, and no significant association between cognitive ability and age of psychosis onset.  
In summary, there is still a lack of evidence of an ‘age of psychosis onset effect’ in youth 
<18 years of age. We lack the knowledge to determine whether psychoses with an onset before 18 
years of age should be differentiated into VEOP and EOP, and if so, whether the traditional age cut-
offs are clinically valid. A better understanding of this is important for the development of 
diagnostic criteria and age-specific therapeutic strategies. Indeed, the urgent need for studies 
investigating the role played by age of onset of psychosis on clinical presentation and response to 
therapeutic interventions has recently been highlighted (Schimmelmann & Schultze-Lutter 2012; 
Schimmelmann et al., 2013; NICE, 2013). 
To our knowledge, no study has investigated the clinical and demographic differences 
between young people with VEOP and EOP at the time of psychosis onset. In the current study, we 
examined psychoses with onset before the age of 18 years by: 1) examining differences at 
presentation between individuals with EOP and VEOP according to the traditional cut-offs for age 
of psychosis onset; and 2) by using receiver operating characteristic (ROC)-curves to determine if 
there was a clinically significant cut-off for the age of psychosis onset in the current sample.  
 
 
2 Methods 
 
2.1 Participants and Procedure 
Participants in this study were 88 (45 female, 43 male) children and adolescents consecutively 
admitted to the Child and Adolescent Neuropsychiatry Unit of the Clinical and Research Hospital 
Bambino Gesù of Rome with a recent onset of psychosis between 2012 and 2014. Patients had 
psychosis onset between ages 6.7 and 17.5 years (M=13.74, SD=2.37, median=14.1) and had no 
previous drug treatment for psychosis (typical/atypical antipsychotics). Specific psychotic 
diagnoses are listed in Table 1. Exclusion criteria were past diagnosis of psychotic disorder, 
traumatic brain injury or known neurological disorder, verbal IQ<70, and current drug or alcohol 
abuse. The participation rate was 95% of the consecutively admitted children/adolescents. Four 
patients (5%) were excluded because of the presence of an exclusion criteria (three due to verbal 
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IQ<70, one due to drug abuse). No eligible patient refused to participate. The study was approved 
by the Ethics Committee of the Clinical and Research Hospital Bambino Gesù of Rome. 
Participants gave written informed assent and written informed consent was given by their 
parents/legal guardian. 
 
2.2 Measures 
Mental disorders were assessed using the Schedule for Affective Disorders and Schizophrenia for 
School Aged Children Present and Lifetime Version (K-SADS-PL) (Kaufman et al., 1997). 
Psychotic symptoms were indexed on the Positive and Negative Syndrome Scale (PANSS) (Kay et 
al., 1987). This 30-item scale is used to assess the severity of positive and negative symptoms of 
psychosis, as well as general psychopathology. Both interviews were administered to the 
participants and their parent/guardian. All participants were screened for autism-spectrum disorder 
using the Autism Quotient Child (Auyeung et al., 2008) or Adolescent (Baron-Cohen et al., 2006) 
versions, completed by participants and their parent/guardian. In the case of positive screening, 
participants were assessed by a trained clinician on the Autism Diagnostic Observation Schedule-
Generic (Lord et al., 2000). None met criteria for autism-spectrum disorder. Participants completed 
(via self-reported) the Multidimensional Anxiety Scale for Children (MASC) (March et al., 1997) to 
obtain an index of the severity of anxiety symptoms and the Children’s Depression Inventory (CDI) 
(Kovacs, 1998) to obtain a global rating of depressive symptoms. Functioning was measured with 
the Childhood Global Assessment Scale (CGAS) (Shaffer et al., 1983). IQ was assessed with the 
Wechsler Intelligence Scale for Children (WISC-III) (Wechsler, 1991). 
Duration of untreated illness (DUI) was defined as the delay between the onset of the first 
psychiatric disorder and the onset of criteria treatment, following the methodology used by 
Keshavan et al. (2003) DUP was defined as the delay between the onset of psychosis and the onset 
of criteria treatment, following the methodology used by Larsen et al. (2001). 
We documented any first-degree relative with psychosis. Nine participants had no available 
information on family history (eight due to adoption). Living in an urban environment within the 
last three years was categorized according to a population of ≤ 100,000 or >100,001 (based on 
Dragt et al., 2011). Socio-demographic information were obtained from parents/guardians. 
 
2.3 Statistical analyses 
First, we divided and compared groups based on traditional cut-offs for age of psychosis onset: 
VEOP (onset of psychosis ≤ 12 years of age) and EOP (onset of psychosis 13-17 years of age). For 
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group comparisons on categorical data, Chi-square was used. Independent Samples Mann-Whitney 
U was employed for group comparisons of continuous data. Effect sizes were calculated with 
Cohen’s d for continuous variables and Cramer’s phi for categorical data. 
To investigate the predictive value of age of onset for psychotic symptom severity and 
functioning, without using the a priori cut-offs between EOP and VEOP, ROC-curves were 
calculated. Traditionally, ROC-curves are used to evaluate the ability of a test to detect a golden 
standard disorder/abnormality. Here, the curves were used in a slightly different context to evaluate 
the prognostic ability of age of onset at different age cut-offs. Thus, instead of evaluating whether, 
based on an a priori cut-off value, a test-score predicted an outcome with sufficient sensitivity 
(SENS) and/or specificity (SPEC), here optimal prediction of the outcome was used as a criterion to 
select the diagnostically most relevant age of onset cut-off. This approach was chosen because: (1) 
it allowed for the identification of an optimal age of onset cut-off (age with optimal SENS/SPEC), 
and; (2) it provided insight into the general prognostic value of age of onset for poor outcome.   
In order to to identify the factors associated with the poorest functioning and most severe 
symptoms using ROC analyses, the highest 25% of PANSS scores were compared to the lowest 
75% of PANSS scores (positive, negative and total), and lowest 25% of CGAS scores were 
compared to the highest 75% of CGAS scores. After calculation of the ROC-curves, the non-
parametric area under the curve (AUC) was investigated. If the AUC was significantly different 
from 0.5 (=chance level prediction), the curve’s SENS and SPEC coordinates were inspected to find 
the age of psychosis onset cut-off with the most optimal SENS/SPEC balance, which was selected 
based on the highest J-statistic (SENS+SPEC-1) (Youden, 1950). Finally, SENS and SPEC were 
investigated for the traditional cut-off between VEOP and EOP. Finally, univariate data was 
reanalysed using the age cut-off shown to be most predictive in ROC analyses. All analyses were 
conducted with IBM SPSS (version 22). 
 
 
3 Results 
 
3.1 Sample characteristics 
The characteristics of the sample are presented in Table 1. The distribution of age of psychosis 
onset is shown in Figure 1. Twenty-nine participants (14 female) were in the VEOP group (mean 
age of psychosis onset=10.97 years; SD=1.58). Fifty-nine participants (31 female) were in the EOP 
group (mean age of psychosis onset=15.11 years; SD=1.20).  
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3.2 VEOP versus EOP 
Psychotic diagnoses and family history of psychiatric illnesses for each group are presented in 
Table 1. There was no significant group difference between VEOP and EOP in terms of gender 
distribution (χ2=0.14, p=0.7, =0.04), urban environment (χ2=0.003, p>0.9, =-0.006), diagnosis of 
schizophrenia as opposed to other psychotic disorders (χ2=0.007, p>0.9, =-0.009), or a family 
history of psychotic illness (χ2=2.21, p=0.14, =-0.17). The VEOP group showed a significantly 
shorter DUI (p=0.005, d=-0.60) and DUP (p=0.03, d=-0.54) than the EOP group. They also had 
lower CGAS scores (p=0.048, d=-0.43). In terms of symptoms, groups did not differ significantly 
on PANSS positive (p=0.7, d=0.15), negative (p>0.9, d=0.04), general (p>0.9, d=0.09) or total 
(p>0.9, d=0.12) subscales, MASC (p=0.2, d=0.28), or CDI (p=0.3, d=0.22) Similarly, IQ scores did 
not differ significantly between groups (p=0.4, d=-0.08).  
 
3.3 ROC-curves 
To investigate whether older age of psychosis onset was predictive of lower psychotic symptom 
severity and better functioning without assuming an a priori cut-off, ROC-curves were calculated 
using age of onset (range: 6.7-17.5 years) as a predictor variable (see Figure 2).  
 
First, the AUCs for the ROCs with different outcomes were investigated to gain an overall insight 
of the prognostic value of age of onset for poor outcome. For the prediction of being in the lower 
three quartiles of PANSS total scores, the AUC was 0.63 and did not differ significantly from 0.5, 
indicating that total symptom severity could not be predicted above chance level by age of 
psychosis onset (95%CI: 0.49-0.78; p=0.066). Being in the lower three quartiles of PANSS negative 
symptom scores was also not predicted above chance level by age of onset, as shown by a low AUC 
that did not differ significantly from 0.5 (AUC=0.59; 95%CI: 0.46-0.72; p=0.24). For the prediction 
of being in the lower three quartiles of PANSS positive symptom scores, the AUC was 0.69 
(95%CI: 0.57-0.80; p=0.012), showing that the age of onset was predictive of positive symptom 
severity. Inspection of the ROC-curve SENS/SPEC coordinates revealed that the  optimal age-cut-
off was 14.0 years. For this cut-off, the J-statistic was highest (J=0.37), indicating an optimal 
combination of SENS (0.62) and SPEC (0.75). In the final ROC-analysis, predictive ability of age 
of onset for being in the upper quartile of CGAS scores was evaluated. Here, the AUC was 0.68 and 
this value was significantly higher than 0.5 (95%CI: 0.53-0.82; p=0.015). This indicated that higher 
age of onset was predictive of better functioning. Inspection of the ROC-curve coordinates showed 
that optimal age of psychosis onset cut-off was 14.7 years: for this cut-off the J-statistic was highest 
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(0.42) and the optimal combination of SENS (0.71) and SPEC (0.70) was observed. These results 
indicated that age of psychosis onset was generally predictive of positive symptomatology and 
functioning, and that setting the age of onset cut-off at <14.0 and <14.7, resulted in optimal 
prediction of, respectively more positive symptomatology and poorer functioning.  
The observed optimal age cut-offs were higher than the cut-off traditionally used to 
differentiate between VEOP and EOP (age of onset ≤12). This age cut-off showed very high SENS 
but low SPEC in the current analyses: SENS=0.81 and SPEC=0.29 for low positive symptom 
severity and SENS=0.81 and SPEC=0.25 for high functioning. 
 
3.4 Secondary analyses 
To investigate the validity of the cut-off of 14-14.7 years of age, univariate analyses were rerun 
dividing groups based on age of psychosis onset <15 (N=56) or ≥15 years of age (N=32). The 
younger group had significantly higher PANSS positive scale scores (p=0.005; d=0.70) and lower 
CGAS scores (p=0.003, d=-0.65), as would be expected from ROC analyses results. They also had 
higher PANSS total symptom scores (p=0.42, d=0.48) and shorter DUI (p=0.004, d=-0.59). There 
were no significant group differences on negative (p=0.16, Cohen’s d=0.35) or general (p=0.4, d 
=0.20) subscales, DUP (p=0.3, d=-0.29), MASC (N=47 and 27, p=0.097, d=0.34), CDI (N=47 and 
28, p=0.8, d=0.05) or IQ scores (p=0.6, d=0.27). In terms of demographic variables, there were no 
significant differences between the new groups in terms of gender distribution (χ2=0.08, p=0.8; 
=0.03), urban environment (χ2=3.35, p=0.067; =-0.2), diagnosis of schizophrenia as opposed to 
other psychotic disorders (χ2=0.04, p=0.8; =-0.02), or a family history of psychotic illness 
(χ2=1.58, p=0.2; =-0.14). 
 
 
4 Discussion 
 
In this study, we investigated whether psychosis with onset before the age of 18 years old should be 
considered a homogenous entity by examining 88 participants aged 6.7 to 17.5 years at the time of 
psychosis onset. This was achieved by comparing groups defined by the traditional cut-offs for 
VEOP (onset ≤12 years) and EOP (onset 13-17 years), and subsequently exploring the data using 
ROC-curves to identify the age of onset cut-off with optimal predictive ability, without setting any a 
priori cut-off. Traditionally defined groups of VEOP and EOP could not be differentiated based on 
demographic factors, clinical symptoms (including psychotic, depressive or anxiety) or IQ. 
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However, those with VEOP showed poorer functioning and shorter DUI and DUP. When data were 
explored using the ROC-analyses without a priori cut-offs, the optimal age of psychosis cut-offs to 
distinguish those with poor outcome from those with more favourable outcome were between 14 
and 14.7 years, with lower levels of positive symptoms and better functioning being predicted by 
older age of onset. When used to predict poor outcomes, the cut-offs within this age range showed 
better SENS and SPEC than the traditional age cut-off of 12 years, which showed particularly poor 
specificity.  
To the best of our knowledge, this is the first study to compare the clinical characteristics of 
EOP and VEOP at the time of diagnosis with psychotic disorder and statistically explore the 
validity of traditional age of onset cut-offs. Rabinowitz and colleagues (2006) used linked 
population-based registry data to empirically investigate the optimal cut-off for age of onset of 
schizophrenia for the long-term course of illness. They found that psychosis onset ≤ age 11 was 
associated with more days in hospital at first admission, and that psychosis onset ≤ age 12 was 
associated with greater number of days in hospital each year.  
In our sample, the traditional age of psychosis onset cut-offs for VEOP and EOP were not 
particularly useful in clinically differentiating participants at presentation. The VEOP group did not 
show significantly higher levels of positive, negative or total symptoms, or depressive and anxiety 
symptoms. One explanation for the lack of group differences is that the CDI and MASC are self-
report and younger children may have difficulty recognizing and describing their emotions. 
However, this was not the case with the PANSS, which is administered by clinicians. In fact, ROC-
curves calculations suggested that the null findings may be attributed to the age of 12 years being an 
inaccurate cut-off for clinical significance of age of psychosis onset, at least for positive symptoms. 
We found that the optimal ages for differentiating the lowest three quartiles on the PANSS positive 
scores from the highest quartile was 14 years, with older age indicating less severe 
psychopathology. This is the same age cut-off used by Biswas and colleagues (2006), who showed 
higher levels of psychotic symptoms in their VEOP group. In our sample, age was not useful for 
differentiating the severity of total or negative symptoms. 
Reanalysis of the data using the age of psychosis onset cut-off of <15 or 15-17 years old 
demonstrated larger effect sizes for the PANSS subscales, DUI, CGAS, and MASC than using the 
traditional age cut-off, although PANSS negative and general subscale scores and MASC did not 
differ significantly between these new groups. The increase in effect size demonstrates that a 
clinically-relevant difference may be present, at least for some symptoms, and that the current study 
may be underpowered to detect some differences. The findings provide tentative affirmation that the 
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age of 15 years may be a more appropriate cut-off for detecting clinical differences in age of 
psychosis onset in children and adolescents, but more studies are needed to confirm this.    
Better psychosocial functioning was associated with an older age of psychosis onset, 
evidenced in the group comparison and ROC-curve calculations. The EOP group showed CGAS 
scores which were on average six points higher than the VEOP group, a finding that was 
statistically significant. Additional ROC-curve calculations provided evidence that an age cut-off of 
14.7 years was even more optimal, with relatively high sensitivity (71%) and specificity (70%) for 
the upper quartile of functioning. This cut-off was better than 12 years of age, which showed high 
sensitivity (81%), but very low specificity (25%) for CGAS scores.  
More impaired psychosocial functioning in individuals with a younger age of psychosis 
onset is likely to reflect the impact of psychosis onset on the establishment of identity formation, 
social networks, and peer relationships, all of which are important developmental aspects of the 
transition into adolescence. Moreover, earlier disruption at school is likely to negatively affect 
academic performance and the behavioural experience of the school environment. Our ROC-curve 
analyses suggest that intervention for these psychosocial disruptions may be particularly important 
for those with onset of psychosis before approximately 14.7 years of age to improve long-term 
functional outcome.  
In this study we also found that DUP and DUI were significantly shorter in the VEOP group 
than EOP. Previous literature suggests that psychosis onset before age 18 is associated with a more 
insidious onset than adult psychosis (Hollis, 2003; Schimmelmann et al., 2007). We propose that 
this may indeed be the case, but that in childhood (i.e. age 12 and earlier), parents are more vigilant 
and attentive to behavioural disorders or social difficulties, leading them to seek intervention 
earlier. This is in contrast to adolescence when young people typically develop a level of 
independence from their parents and it is more difficult to distinguish typical behavioural anomalies 
associated with being a teenager from early manifestations of psychotic condition. However, our 
data and this hypothesis are contradictory to a previous finding of more insidious onset of psychosis 
in VEOP compared psychosis onset at an older age (Russell, 1994). Given the well-established 
association between prolonged DUP and poor outcome, further research into the factors associated 
with DUP in children and adolescents is necessary. 
There were a number of null findings from the comparison of VEOP and EOP. These 
included IQ, gender distribution, urbanicity, psychotic diagnosis and family history of psychosis. 
Similar to the findings of Rhinewine et al. (2005), our VEOP group did not have poorer IQ than the 
EOP group, whereas Biswas and colleagues (2006) found a significant difference between their 
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childhood and adolescent groups on indices of IQ. This discrepancy is likely due to the fact that 
cognition was assessed an average of over 12 years after illness onset in the Biswas et al. (2006) 
sample, whereas our participants were assessed at illness onset and those reported by Rhinewine et 
al. (2005) had an average illness duration of 4 years. Given that the progression of cognitive 
changes in VEOP and EOP are largely unknown, deterioration in cognitive ability may occur in the 
years following diagnosis.  
While there is evidence of a greater proportion of males (Russell, 1994) and a stronger 
genetic loading (Kumra & Schulz, 2008) in individuals who develop psychosis before the age of 18, 
to the best of our knowledge, no study has compared VEOP and EOP these demographic variables. 
Our findings suggest that in demographic and diagnostic respects, onset of psychosis before age 18 
is somewhat homogenous. When univariate analyses were rerun by dividing the sample into 
psychosis onset <15 years vs. onset 15- 17 years), there were no significant group differences on 
demographic and diagnostic variables, providing further evidence of homogeneity in these respects 
in our sample. 
The strengths of this study are a rare sample of individuals with a low prevalence disorder 
and no previous drug treatment for psychosis. The sample was recruited from a hospital considered 
to be the Italian point of reference for the assessment and treatment of VEOP/EOP and is likely to 
be highly representative. This differs from many other VEOP/EOP samples, where referrals are 
often treatment-refractory patients from other medical centres. This study has several limitations. 
First, a sample size of 88 patients is not particularly large for ROC analyses, and we may have been 
underpowered to detect significant group difference. However, this sample size should be 
considered in light of the low prevalence of psychotic disorder in the age range investigated.  
Second, a full neurocognitive assessment was not conducted. Third, only a history of first-degree 
relatives was assessed. Second-degree relatives with psychosis may also infer increase genetic risk 
for the illness. Fourth, the cross-sectional design of the current study precluded the analysis of the 
possible role played by the age of onset on the longer clinical and functional out come. 
In summary, we found that the traditional cut-off for age of psychosis onset of ≤ 12 years for 
VEOP and 13-17 years for EOP were not particularly meaningful for describing the initial clinical 
presentation of this sample. ROC-curve calculations demonstrated that a more optimal age cut-off 
would fall between 14 and 14.7 years, particularly in terms of specificity for positive psychotic 
symptoms and functioning. We recognise that sensitivity of 62% and specificity of 75%, and 
sensitivity of 70% and specificity of 71% for positive symptoms and functioning respectively are 
not excellent prognostic values, particularly in light of the null findings for negative and general 
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symptoms. However, our aim was not to determine the best prediction, but rather to gain insight 
into the clinical significance of the traditional age cut-offs for VEOP and EOP, and explore if there 
was a more appropriate cut-off. Our results suggest more investigation is required. There is a need 
for more in-depth studies into the developmental features of psychoses with an onset in childhood 
and adolescence. Future research should incorporate a comprehensive neurocognitive battery and 
neuroimaging to characterise the association between neurodevelopment and age of psychosis 
onset. Follow-up of this sample will allow us to investigate later outcome in relation to age of 
psychosis onset, and the associations between early presentation and outcome.  
There is a temptation to apply adult models of schizophrenia and other psychoses to children 
and adolescents. A clearer understanding of the age-specific aspects of psychotic disorder will aid 
the development of predictive diagnostic tools, more accurate prognosis prediction, and more 
effective and age-tailored therapeutic interventions. Indeed, the question of whether or not to 
provide specific age-tailored therapeutic interventions in patients who develop schizophrenia before 
the age of 18 years is still under debate (Armando et al, 2015; Tiffin et al, 2013). In accordance with 
the preliminary evidence emerging from our findings, we could speculate that the classical 
distinction between VEOP and EOP is not a useful tool. Psychosocial interventions to improve 
social and general functioning could be of particular usefulness under the age of 15 years old. The 
lack of relevant differences in terms of cognitive functioning, negative, depressive and anxiety 
symptoms, lead to a preliminary hypothesis that those symptoms and aspects of psychosis should be 
the target of any treatment, regardless the age of onset.  
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Response to Reviewers' Comments: 
 
We thank the reviewers for their scrutiny of the manuscript and insightful remarks, their 
excellent feedback on our study was very encouraging. We hope to match their 
thoroughness and detail in our reply. 
Please note that our replies are written in italics and that any changes to the text are 
additionally underlined. 
 
 
 
Reviewer #1: Thank you for asking me to review this manuscript. I am sorry to say that the 
study involves a non-question. The distinction of psychosis to early, very early and so on is 
and has always been an artefact of psychiatric service and training organization. By 
definition, different services and psychiatrists with different training would see these patients 
based on their age at presentation because of the division of services to pediatric, 
adolescent adult etc 
Schizophrenia at any age is known to describe a heterogenous population in terms of 
symptom profiles and most likely etiology. Does age of onset mean anything specific? Yes, it 
is an indicator of severity of brain dysfunction that is likely to be unrelated to any specific 
schizophrenia-related mechanism and likely to be accounted for by the very early disruption 
to development introduced by disease mechanisms. As in all of medicine, early onset of 
anything is associated with greater severity and greater dysfunction in all aspects of life. And 
obviously, the young you are when you go psychotic the more likely that someone will notice 
because children live in highly structured environments that include school and home where 
significant deviance is likely to be detected and acted upon.  
 
Response: We have altered the emphasis of this paper to demonstrate the heterogeneity of 
schizophrenia and psychotic illness (see below). We note that this is not a comparison of 
adults and children with psychosis, but rather an investigation of the age of onset within a 
child/adolescent population. Little investigation has been conducted on the clinical 
presentation (and indeed degree of brain dysfunction) of individuals who develop psychotic 
illness within this population.  Moreover, our findings suggest that within the child/adolescent 
population, younger children may not show a greater degree of brain dysfunction (as 
evidenced by equivalent IQ scores). We acknowledge in the text that a short DUP is likely to 
be the result of earlier detection by parents, but highlight that this finding is not consistent 
(i.e. EOP has previously been associated with a more insidious onset). It is our belief that 
investigations of this kind are necessary for informing psychosocial and psychological 
interventions.  
 
“Schizophrenia is a heterogeneous clinical syndrome of unknown aetiology, comprising a 
number of psychopathological domains and patients vary considerably in which pathologies 
are manifest (Insel, 2010). In accordance with this definition, symptoms of schizophrenia are 
heterogeneous, even within the same age group (Carpenter & Buchanan, 1989). Besides the 
heterogeneity of the clinical presentation, some differences related to the age of onset (i.e. 
premorbid abnormalities, longer duration of untreated psychosis [DUP], poorer outcome) 
have been highlighted (Armando et al, 2015). Consequently, the need of age-specific 
research in the area of psychosocial treatments for children and adolescents with 
schizophrenia has been argued (Tiffin et al, 2013).” (p.3). 
 
 
Reviewer #2: This is a very well-written paper with a clear and clinically-relevant rationale. 
As noted by the authors, this is a very under-researched group due to the low prevalence of 
early onset psychosis. I have only minor comments to the authors:  
*Response to Reviewers
 
1. Methods: All data appears to be derived directly from the child patients themselves (except 
demographics presumably, although this is not specifically noted, could this please be 
clarified in the text where appropriate), were any symptom measures etc completed via 
parent-report? For this younger age group, parent-report might be helpful, if this is not 
available then worth mentioning in the limitations section.  
 
Response: Information obtained via parents/guardians are very useful in this age range. The 
K-SADS, the PANSS and the AQ were administered to both patients and parents together. In 
order to provide this important information, we have revised the text as following:  
 
"Mental disorders were assessed using the Schedule for Affective Disorders and 
Schizophrenia for School Aged Children Present and Lifetime Version (K-SADS-PL) 
(Kaufman et al., 1997). Psychotic symptoms were indexed on the Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987). This 30-item scale is used to assess the 
severity of positive and negative symptoms of psychosis, as well as general 
psychopathology. Both interviews were administered to the participants and their 
parent/guardian. All participants were screened for autism-spectrum disorder using the 
Autism Quotient Child (Auyeung et al., 2008) or Adolescent (Baron-Cohen et al., 2006) 
versions, completed by participants and their parent/guardian. In the case of positive 
screening, participants were assessed by a trained clinician on the Autism Diagnostic 
Observation Schedule-Generic (Lord et al., 2000). None met criteria for autism-spectrum 
disorder. Participants completed (via self-reported) the Multidimensional Anxiety Scale for 
Children (MASC) (March et al., 1997) to obtain an index of the severity of anxiety symptoms 
and the Children’s Depression Inventory (CDI) (Kovacs, 1998) to obtain a global rating of 
depressive symptoms. Functioning was measured with the Childhood Global Assessment 
Scale (CGAS) (Shaffer et al., 1983). IQ was assessed with the Wechsler Intelligence Scale 
for Children (WISC-III) (Wechsler, 1991).” (p5). 
 
 
2. Statistical analyses: The way in which the outcome variables are described is confusing 
and a bit repetitive, why not list all variables for which the lowest 75% were compared with 
the highest 25% and vice versa rather than repeat cut-offs for each variables? Some context 
here might be helpful, i.e., we wanted to identify the factors associated with the poorest 
functioning and most severe symptoms and therefore dichotomised variables as follows......  
 
Response: Thank you for highlighting this confusion. We have amended the text according to 
this suggestion as follows: 
 
“In order to to identify the factors associated with the poorest functioning and most severe 
symptoms using ROC analyses, the highest 25% of PANSS scores were compared to the 
lowest 75% of PANSS scores (positive, negative, general and total), and lowest 25% of 
CGAS scores were compared to the highest 75% of CGAS scores.” (p. 6) 
 
 
3. Statistical analyses/results: ROC and AUC statistics are not commonly used in this area of 
research and are often poorly described and misunderstood. It is therefore very important 
that the authors correctly describe these statistics and their meaning, not only in the 
methods, but also reiterated in the results and discussion. Also with regards to sensitivity and 
specificity, as these statistics are not used in the typical way in this study (i.e., to determine 
how well a screening test compares with a gold standard) it would be helpful to explain how 
these statistics are useful for addressing the aims of the current study and put their findings 
into words rather than just quoting the values. In the Results and Discussion sections I think 
the findings related to these analyses could be more clearly described.  
 
Response: We agree that our use of ROC curves and the associated AUCs is somewhat 
different from how they are regularly used (i.e. evaluation of test vs. golden standard). We 
have therefore amended the Methods section to clarify our research goals and how 
ROC/AUC methods were useful to attain them. We have also added clarifications in the 
Results and Discussion sections. We hope that these made our aims and procedures clearer 
to the reader.  
 
In the Methods section, we added the following test:  
 
“…Traditionally, ROC-curves are used to evaluate the ability of a test to detect a golden 
standard disorder/abnormality. Here, the curves were used in a slightly different context: to 
evaluate the prognostic ability of age of onset at different age cut-offs. Thus, instead of 
evaluating whether a test-score predicted an outcome with sufficient sensitivity (SENS) 
and/or specificity (SPEC), here optimal prediction of the outcome was used as a criterion to 
select the diagnostically most relevant age of onset cut-off. This approach was chosen 
because: (1) it allowed for the identification of an optimal age of onset cut-off (age with 
optimal SENS/SPEC), and; (2) it provided insight into the general prognostic value of age of 
onset for poor outcome….” (p 5-6).  
 
In the results section, we further clarified the text: 
 
“…First, the AUCs for the ROCs with different outcomes were investigated to gain an overall 
insight into the prognostic value of age of onset for poor outcome. For the prediction of being 
in the lower three quartiles of PANSS total scores, the AUC was 0.63 and did not differ 
significantly from 0.5, indicating that total symptom severity could not be predicted above 
chance level by age of psychosis onset (95%CI: 0.49-0.78; p=0.066). Being in the lower 
three quartiles of PANSS negative symptom scores was also not predicted above chance 
level by age of onset, as shown by a low AUC that did not differ significantly from 0.5 
(AUC=0.59; 95%CI: 0.46-0.72; p=0.24). For the prediction of being in the lower three 
quartiles of PANSS positive symptom scores, the AUC was 0.69 (95%CI: 0.57-0.80; 
p=0.012), showing that the age of onset was predictive of positive symptom severity. 
Inspection of the ROC-curve SENS/SPEC coordinates revealed that the optimal age-cut-off 
was 14.0 years. For this cut-off, the J-statistic was highest (J=0.37), indicating an optimal 
combination of SENS (0.62) and SPEC (0.75). In the final ROC-analysis, predictive ability of 
age of onset for being in the upper quartile of CGAS scores was evaluated. Here, the AUC 
was 0.68 and this value was significantly higher than 0.5 (95%CI: 0.53-0.82; p=0.015). This 
indicated that higher age of onset was predictive of better functioning. Inspection of the ROC-
curve coordinates showed that optimal age of psychosis onset cut-off was 14.7 years: for this 
cut-off the J-statistic was highest (0.42) and the optimal combination of SENS (0.71) and 
SPEC (0.70) was observed. These results indicated that age of psychosis onset was 
generally predictive of positive symptomatology and functioning, and that setting the age of 
onset cut-off at <14.0 and <14.7, respectively resulted in optimal prediction of more positive 
symptomatology and poorer functioning. …” (p 7) 
 
In the Discussion section, we further clarified what our results: 
 
“… When data were explored using the ROC-analyses without a priori cut-offs, the optimal 
age of psychosis cut-offs to distinguish those with poor outcome from those with more 
favourable outcome were between 14 and 14.7 years, with lower levels of positive symptoms 
and better functioning being predicted by older age of onset. When used to predict poor 
outcomes, the cut-offs within this age range showed better SENS and SPEC than the 
traditional age cut-off of 12 years, which showed particularly poor specificity…” (p 8) 
 
 
4. Results: a very obvious follow-up question from the analyses is whether there are 
demographic and/or clinical differences between groups when the ROC-defined cut-off is 
used (i.e., 14-15 years). That is, the authors conclude that the current age cut-off has little 
validity as there are few clinical factors distinguishing the groups, yet do not state whether 
their cut-off might be better. Later in the discussion it seems as though these analyses have 
actually been conducted and so I would recommend that these are quoted in the Results 
even if the answer is that they are not in fact better at distinguishing. This should also be 
discussed, i.e., why would the ROC indicate a different age cut-off that then can't perform 
better in initial analyses - is the study underpowered? 
 
Response: As suggested we have included the analyses of the cut-off indicated in ROC 
analyses, as well as highlighting the fact that this study may be underpowered. 
 
The following has been added to the Results section: 
 
“To investigate the validity of the cut-off of 14-14.7 years of age, univariate analyses were 
rerun dividing groups based on age of psychosis onset <15 (N=56) or ≥15 years of age 
(N=32). The younger group had significantly higher PANSS positive scale scores (p=0.005; 
d=0.70) and lower CGAS scores (p=0.003, d=-0.65), as would be expected from ROC 
analyses results. They also had higher PANSS total symptom scores (p=0.42, d=0.48) and 
shorter DUI (p=0.004, d=-0.59). There were no significant group differences on negative 
(p=0.16, Cohen’s d=0.35) or general (p=0.4, d =0.20) subscales, DUP (p=0.3, d=-0.29), 
MASC (N=47 and 27, p=0.097, d=0.34), CDI (N=47 and 28, p=0.8, d=0.05) or IQ scores 
(p=0.6, d=0.27).  In terms of demographic variables, there was no significant differences 
between the new groups in terms of gender distribution (χ2=0.08, p=0.8; =0.03), urban 
environment (χ2=3.35, p=0.067; =-0.2), diagnosis of schizophrenia as opposed to other 
psychotic disorders (χ2=0.04, p=0.8; =-0.02), or a family history of psychotic illness 
(χ2=1.58, p=0.2; =-0.14).” (p.8) 
  
The following has been added to the Discussion section:  
 
“Reanalysis of the data using the age of psychosis onset cut-off of <15 or 15-17 years 
old demonstrated larger effect sizes for the PANSS subscales, DUI, CGAS, and MASC than 
using the traditional age cut-off, although PANSS negative and general subscale scores and 
MASC did not differ significantly between these new groups. The increase in effect size 
demonstrates that a clinically-relevant difference may be present, at least for some 
symptoms, and that the current study may be underpowered to detect some differences. The 
findings provide tentative affirmation that the age of 15 years may be a more appropriate cut-
off for detecting clinical differences in age of psychosis onset in children and adolescents, but 
more studies are needed to confirm this.” (p 9) 
 
“……When univariate analyses were rerun by dividing the sample into psychosis onset <15 
years vs. onset 15- 17 years), there were no significant group differences on demographic 
and diagnostic variables, providing further evidence of homogeneity in these respects in our 
sample.” (p11) 
 
 
5. Table 1. Can the authors please add the associated statistics to Table 1 (i.e., group 
comparisons on demographic and clinical variables). In addition, might it be helpful to 
compute effect sizes (standardised mean differences and odds ratios). It looks like some of 
the differences are actually quite large but did not meet statistical significance - I think it 
would be worth taking a look at the effect sizes as this might just be a power issue.  
 
Response: We thank the reviewer for this useful suggestion. Statistics and effect sizes are 
now included in text and in the table. Effect sizes have been calculated using Cohen’s d and 
Cramer’s phi. 
 
 
 
Reviewer #3: This manuscript compares demographic and clinical characteristics in children 
with very early onset psychosis (VEOP <=12 years) and early onset psychosis (EOP; 13-17 
years), firstly employing the traditional cut-offs, and then using ROC curves to determine 
optimal age-cut offs for differentiating VEOP and EOP characteristics. 
The manuscript is well written, and the analyses appear to be performed competently.  
Main points for consideration: 
 
1. As a non-expert in ROC analytic methods, I was left wondering whether the integrity of this 
analysis is susceptible to the poor distribution of cases in the VEOP group, and further, 
whether it is susceptible to the imbalance in cases between the groups (VEOP 33%; EOP 
66%).  
 
Response: The non-normal/irregular distribution of the age of onset within the VEOP group 
and across the VEOP and EOP groups, which were merged for the ROC analyses, is not 
problematic for the current analyses, because we used non-parametric methods that are not 
distorted by irregular/non-normal distributions of the predictor.  
In the ROC-analyses we use age of onset as the predictor and poor outcome (as 
defined by PANSS scores) as outcome. For each cut-off on the age of onset predictor 
variable, the sensitivity and specificity with regard to the outcome were estimated. The SENS 
and SPEC for each cut-off were next plotted in the ROC curve. The AUC, which is used to 
judge the predictive ability of the predictor for the used outcome can be computed in different 
ways. One (parametric) way would be to fit a smooth curve through the coordinates and 
estimate the AUC under this curve. This AUC would be sensitive to distortions when the 
points in the ROC curve are not regularly spread out, as is the case in our study. We 
therefore used a non-parametric method to calculate the AUC. In this method, the points in 
the ROC curve are connected by lines and the exact AUC for the resulting (rather jagged) 
curve, is calculated using trapezoid formulas. The resulting AUC is estimated under 
distribution free assumptions. We clarified our use of non-parametric AUCs in the text (p 5-
6).  
 
 
2. The paper argues the importance of the topic on the basis of informing diagnostic criteria 
development and age-specific therapeutic strategies. These arguments could be better 
supported by the inclusion of outcome data on these cases (while this is acknowledged as a 
limitation, if the data is available, it should be included). Also, there is no discussion of how 
age-specific therapies would be targeted on the basis of limited differences in clinical 
presentation rather than age-appropriate tailoring based on capacity to understand 
psychotherapy materials etc.; nor is the case for pharmacological therapy distinction clear for 
<=age 12 years vs. the revised recommendation of <=14.7 years. In other words, the 
significance of the finding is relatively limited, particularly given that on the majority of clinical 
measures (e.g., depression, anxiety, negative and total symptoms) no differences were 
observed. 
 
Response: We agree with the reviewer’s comment. Indeed it would be very helpful to have 
longitudinal data on the outcome to give a better support to the current findings. 
Unfortunately, as stated in the paper, this data is not available at the moment. In order to 
highlight this limitation, we added the following sentence in the Limitation section:  
 
“Fourth, the cross-sectional design of the current study precluded the analysis of the possible 
role played by the age of onset on the longer clinical and functional out come.”(p.11) 
 
Regarding the second comment, we believe that the finding of a lack of relevant age-related 
clinical differences is a relevant finding in itself in term of treatment. Indeed, if these findings 
will be replicated and supported by longitudinal studies, the conclusion, as the reviewer says, 
would be that the same treatments should be provided regardless to the age of onset and 
that the only variable that should be taken into account would be the capacity to understand 
psychotherapy materials, etc. Nevertheless, we have added to the Discussion section with 
reflections on this important topic:  
 
“Indeed, the question of whether or not to provide specific age-tailored therapeutic 
interventions in patients who develop schizophrenia before the age of 18 years is still under 
debate (Armando et al, 2015; Tiffin et al, 2013). In accordance with the preliminary evidence 
emerging from our findings, we could speculate that the classical distinction between VEOP 
and EOP is not a useful tool. Psychosocial interventions to improve social and general 
functioning could be of particular usefulness under the age of 15 years old. The lack of 
relevant differences in terms of cognitive functioning, negative, depressive and anxiety 
symptoms, lead to a preliminary hypothesis that those symptoms and aspects of psychosis 
should be the target of any treatment, regardless the age of onset.” (p.12) 
 
3. The method refers to consecutive presentations being included in the study, and exclusion 
criteria are listed. No information regarding the number of presentations and exclusions is 
provided. 
 
Reponses: In accordance with the reviewer comment, we added this information in the text 
as follows:  
 
"The participation rate was 95% of the consecutively admitted children/adolescents.  Four 
patients (5%) were excluded because of the presence of an exclusion criteria (three due to 
verbal IQ<70, one due to drug abuse). No eligible patient refused to participate." 
 
 
4. Only a history of first-degree relatives was assessed. Discussion needs to acknowledge 
this limitation. 
 
Response: We added this as a limitation in the Discussion as follows:  
 
"Third, only a history of first-degree relatives was assessed. Second-degree relatives with 
psychosis may also infer increase genetic risk for the illness." (p 4) 
 
 
Minor points: 
 
1. Table 1 clarity would be improved by the inclusion of subheadings/subsections (e.g., 
Diagnosis; Family History etc.) - presently, it is difficult to distinguish these related pieces of 
information from other variables. 
 
 
Response: Thank you for this comment. Table 1 has been amended as suggested. 
 
 Table 1. Sample characteristics 
 
*
Diagnosis of schizophrenia compared to any other psychotic disorder, 
**
Family history of psychosis compared 
to having family history of non-psychotic psychiatric disorder or no family history of psychiatric disorder. 
Abbreviations: DUI, duration of untreated illness; DUP, duration of untreated psychosis; PANSS, positive and 
negative symptom scale; CGAS, Childhood Global Assessment Scale, IQ, Intelligence Quotient; MASC, 
Multidimensional Anxiety Scale for Children; CDI, Children’s Depression Inventory; FH, family history. 
 Full sample VEOP EOP Statistics Effect size 
 N M SD N M SD N M SD  Cohen’s d 
Clinical characteristics            
Age of psychosis onset 
(years) 
88 13.75 2.37 29 10.97 1.58 59 15.11 1.20 p<0.001 -3.10 
DUI (weeks) 88 67.94 38.51 29 53.07 35.76 59 75.25 37.98 p=0.005 -0.60 
DUP (weeks) 88 29.33 19.39 29 22.45 14.97 59 32.71 20.50 p=0.032 -0.54 
PANSS Positive  88 24.45 6.30 29 25.10 6.50 59 24.14 6.23 p=0.7 0.15 
PANSS Negative  88 23.64 9.14 29 23.86 10.38 59 23.53 8.56 p>0.9 0.04 
PANSS General  88 40.23 12.20 29 41.00 13.41 59 39.85 11.66 p>0.9 0.09 
PANSS Total  88 88.16 20.57 29 89.79 22.94 59 87.36 19.46 p=0.9 0.12 
CGAS  88 34.00 11.93 29 30.59 12.76 59 35.68 11.24 p=0.048 -0.43 
IQ 88 87.72 19.90 29 86.66 19.05 59 88.24 20.44 p=0.4 -0.08 
MASC anxiety scale  74 58.07 11.81 23 60.30 11.30 51 57.06 12.00 p=0.2 0.28 
CDI depression scale  75 20.81 9.69 23 22
.
30 8
.
82 52 20.15 10.06 p=0.3 0.22 
  N %  N %  N %  
Cramer’s 
phi 
Female Gender  45 51.1  14 48.3  31 52.5 χ2=0.14,p=0.7 0.04 
Urbanicity >100,000  55 62.5  18 62.1  37 62.7 χ2=0.003,p>0.9 -0.006 
Diagnosis            
Schizophrenia disorder  48 54.5  16 55.2  32 54.2 χ2=2.21,p=0.14* -0.009 
Schizoaffective disorder  23 26.1  5 17.2  18 30.5   
Schizophreniform disorder  14 15.9  6 20.7  8 13.6   
Bipolar disorder with 
psychotic features 
 3 3.4  2 6.9  1 1.7   
Family history (FH)            
FH psychotic disorder  20 22.7  9 31.0  11 18.6 χ2=0.007,p>0.9** -0.17 
FH non-psychotic bipolar 
disorder 
 11 12.5  4 13.8  7 11.9   
FH non-psychotic 
depressive disorder 
 8 9.1  2 6.9  6 10.2   
FH other psychiatric 
disorder 
 14 15.9  4 13.8  10 16.9 
  
FH unknown   9 10.2  4 13.7  5 8.5   
No FH  26 29.5  6 20.7  20 33.9   
Table(s)
  
 
Figure 1. Distribution of age of psychosis onset in the sample 
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Figure 2. ROC curves  
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